Ridaforolimus is a semisynthetic macrocyclic lactone prepared from rapamycin by selective alkylation of the 42-hydroxy group with a dimethylphosphinate moiety. Ridaforolimus is extensively cited in the literature with over 70 citations.
Ridaforolimus is soluble in ethanol, methanol, DMF or DMSO.
Ridaforolimus is soluble in ethanol, methanol, DMF or DMSO.
| Mechanism of Action | Ridaforolimus binds to receptor protein, FKBP12. This complex then binds to mTOR preventing its interaction with target proteins. |
| References | Phosphorus-containing compounds and uses thereof. Metcalf C.A. et al. US Patent 7,091,213, 2006. Targeting the mTOR pathway using deforolimus in cancer therapy. Mahalingam D. et al. Future Oncol. 2009, 5, 291. |